Stocks · News reference
Alpha Buying: When a CEO Spends $5 Million on His Own Stock, Pay Attention
Corporate executives say optimistic things about their companies every day. They appear on earnings calls, investor presentations and financial television programs to explain why the latest disappointing quarter is
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
UBS Maintains Buy on Hamilton Lane, Raises Price Target to $131
UBS analyst Michael Brown maintains Hamilton Lane (NASDAQ:HLNE) with a Buy and raises the price target from $114 to $131.
Oppenheimer Maintains Outperform on Hamilton Lane, Raises Price Target to $182
Oppenheimer analyst Chris Kotowski maintains Hamilton Lane (NASDAQ:HLNE) with a Outperform and raises the price target from $174 to $182.
Keefe, Bruyette & Woods Maintains Outperform on Hamilton Lane, Raises Price Target to $116
Keefe, Bruyette & Woods analyst Kyle Voigt maintains Hamilton Lane (NASDAQ:HLNE) with a Outperform and raises the price target from $105 to $116.
Wall Street Rallies as Fed’s Waller Hints at September Rate Hold: Stock Market Today
Stocks rallied and Treasury yields retreated from three-year highs after Fed Governor Waller signaled he could back a rate hold, sending bitcoin above $80,000.
Better Cancer Therapy Than Keytruda? Summit Therapeutics Partner's Ivonescimab Outperforms in Lung Cancer Study
Summit Therapeutics' partner Akeso reported positive overall survival results for ivonescimab in a Phase 3 lung cancer clinical trial.